Brief: Milestone Pharmaceuticals Submits New Drug Application to the U.S. FDA for Etripamil
24/10/2023 12:07
Oct 24 (Reuters) - Milestone Pharmaceuticals Inc
MIST.O :
* MILESTONE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG
APPLICATION TO THE U.S. FDA FOR ETRIPAMIL
* MILESTONE PHARMACEUTICALS INC - SUBMISSION SEEKS APPROVAL
FOR
TREATMENT OF AN ABNORMAL HEART RHYTHM, PAROXYSMAL
SUPRAVENTRICULAR TACHYCARDIA OR PSVT
Source text for Eikon: ID:nCNWvP9JTa
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview